Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Melanoma 2Uterine Cervical Neoplasms 1Pancreatic Adenocarcinoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Esophageal Neoplasms 1Brain Neoplasms 1Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

Gemcitabine 4Fluorouracil 4dehydroftorafur 3Taxes 3Oxaliplatin 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3Radiotherapy 2Leucovorin 2Irinotecan 2tocilizumab 1selicrelumab 1niraparib 1indusatumab 1cobimetinib 1atezolizumab 1X-Rays 1Tiragolumab 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Image-Guided 1Radiation 1Pancreatectomy 1PEGPH20 1Nivolumab 1Losartan 1Ipilimumab 1Folfox protocol 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Pancreatic Adenocarcinoma × Tiragolumab × Clear all
NCT03193190 2025-11-21

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Hoffmann-La Roche

Phase 1/2 Completed
341 enrolled 28 charts
Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡